Glucagon-Like Peptide 1 Increases Secretory Burst Mass of Pulsatile Insulin Secretion in Patients With Type 2 Diabetes and Impaired Glucose Tolerance
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The insulinotropic gut hormone glucagon-like peptide (GLP)-1 increases secretory burst mass and the amplitude of pulsatile insulin secretion in healthy volunteers without affecting burst frequency. Effects of GLP-1 on secretory mechanisms in type 2 diabetic patients and subjects with impaired glucose tolerance (IGT) known to have impaired pulsatile release of insulin have not yet been studied. Eight type 2 diabetic patients (64 ± 9 years, BMI 28.9 ± 7.2 kg/m2, HbA1c 7.7 ± 1.3%) and eight subjects with IGT (63 ± 10 years, BMI 31.7 ± 6.4 kg/m2, HbA1c 5.7 ± 0.4) were studied on separate occasions in the fasting state during the continued administration of exogenous GLP-1 (1.2 pmol · kg−1 · min−1, started at 10:00 p.m. the evening before) or placebo. For comparison, eight healthy volunteers (62 ± 7 years, BMI 27.7 ± 4.8 kg/m2, HbA1c 5.4 ± 0.5) were studied only with placebo. Blood was sampled continuously over 60 min (roller-pump) in 1-min fractions for the measurement of plasma glucose and insulin. Pulsatile insulin secretion was characterized by deconvolution, autocorrelation, and spectral analysis and by estimating the degree of randomness (approximate entropy). In type 2 diabetic patients, exogenous GLP-1 at ∼90 pmol/l improved plasma glucose concentrations (6.4 ± 2.1 mmol/l vs. placebo 9.8 ± 4.1 mmol/l, P = 0.0005) and significantly increased mean insulin burst mass (by 68%, P = 0.007) and amplitude (by 59%, P = 0.006; deconvolution analysis). In IGT subjects, burst mass was increased by 45% (P = 0.019) and amplitude by 38% (P = 0.02). By deconvolution analysis, insulin secretory burst frequency was not affected by GLP-1 in either type 2 diabetic patients (P = 0.15) or IGT subjects (P = 0.76). However, by both autocorrelation and spectral analysis, GLP-1 prolonged the period (lag time) between subsequent maxima of insulin concentrations significantly from ∼9 to ∼13 min in both type 2 diabetic patients and IGT subjects. Under placebo conditions, parameters of pulsatile insulin secretion were similar in normal subjects, type 2 diabetic patients, and IGT subjects based on all methodological approaches (P > 0.05). In conclusion, intravenous GLP-1 reduces plasma glucose in type 2 diabetic patients and improves the oscillatory secretion pattern by amplifying insulin secretory burst mass, whereas the oscillatory period determined by autocorrelation and spectral analysis is significantly prolonged. This was not the case for the interpulse interval determined by deconvolution. Together, these results suggest a normalization of the pulsatile pattern of insulin secretion by GLP-1, which supports the future therapeutic use of GLP-1–derived agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Approximate entropy as a measure of system complexity.
Pincus, S. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.6.2297 · Cited by 5,811 · cited 3×
“Synthetic GLP-1[7-36] amide was purchased from Saxon Biochemicals (Hannover, Germany; lot number FGLP 7369301 A, net peptide content 88.”
BackgroundMethodNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationImpaired Pulsatile Secretion of Insulin in Relatives of Patients with Non-Insulin-Dependent Diabetes
O'Rahilly, S., Turner, R. C., & Matthews, D. R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181902 · Cited by 540
Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus
Ward, W. K., Bolgiano, D. C., McKnight, B., Halter, J. B., & Porte, D. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111542 · Cited by 483 · cited 3×
“Synthetic GLP-1[7-36] amide was purchased from Saxon Biochemicals (Hannover, Germany; lot number FGLP 7369301 A, net peptide content 88.”
BackgroundMethodBrief, Irregular Oscillations of Basal Plasma Insulin and Glucose Concentrations in Diabetic Man
Lang, D. A., Matthews, D. R., Burnett, M., & Turner, R. C. (1981) · Diabetes · doi:10.2337/diab.30.5.435 · Cited by 279
Cited by
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1093 · Cited by 297
“00/0 The Journal of Clinical Endocrinology & Metabolism 90(11):5991–5997”
BackgroundSelf-citationJanssen, J. A. M. J. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157797 · Cited by 294
Glucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
“There is compelling evidence that GLP-1 stimulates glucose-dependent insulin secretion (Figure 5 [30,52,78,79]), restores first-phase insulin secretion [80,263], and amplifies pulsatile burst mass in type 2 diabetes [264,265].”
BackgroundSelf-citation
Metadata
- Authors
- Ritzel, R., Schulte, M., Pørksen, N., Nauck, M. S., Holst, J. J., Juhl, C., März, W., Schmitz, O., Schmiegel, W. H., & Nauck, M. A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2001-04-01
- Volume
- 50
- Issue
- 4
- Pages
- 776-784
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2150865391
- Cited by
- 62
- References
- 7
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-Like Peptide 1 Increases Secretory Burst Mass of Pulsatile Insulin Secretion in Patients With Type 2 Diabetes and Impaired Glucose Tolerance. https://app.cochat.ai/papers/10.2337/diabetes.50.4.776
- The paper
- Ritzel, R., Schulte, M., Pørksen, N., Nauck, M. S., Holst, J. J., Juhl, C., März, W., Schmitz, O., Schmiegel, W. H., & Nauck, M. A. (2001). Glucagon-Like Peptide 1 Increases Secretory Burst Mass of Pulsatile Insulin Secretion in Patients With Type 2 Diabetes and Impaired Glucose Tolerance. Diabetes. https://doi.org/10.2337/diabetes.50.4.776
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.